Form 4: Xeris Biopharma COO Sells 15,000 Shares

Kevin McCulloch, President and COO of Xeris Biopharma Holdings, Inc., sold 15,000 shares of common stock at $8 per share through a pre-arranged Rule 10b5-1 trading plan.

Summary

• Kevin McCulloch, President and Chief Operating Officer of Xeris Biopharma Holdings, Inc. (XERS), reported a sale of common stock.
• The transaction involved the disposition of 15,000 shares of common stock.
• The shares were sold at a price of $8 per share.
• The transaction occurred on January 8, 2026.
• This sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by the reporting person.
• Following this transaction, Kevin McCulloch directly beneficially owns 1,685,426 shares of common stock.
• Additionally, 25,000 shares are indirectly beneficially owned by his spouse, for which the reporting person disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 4

Explanation: The sale of shares by a key executive, even if pre-planned, is generally viewed with slight negativity by the market as it reduces the insider's direct stake. However, the Rule 10b5-1 plan mitigates some of the negative sentiment by indicating a pre-scheduled transaction rather than an immediate reaction to new information.

Negatives

• An insider, specifically the President and COO, sold 15,000 shares of company stock.
• While executed under a Rule 10b5-1 plan, insider selling can sometimes be interpreted by the market as a lack of confidence in the company's near-term prospects, or a move to diversify holdings.

Risks

• Potential negative market perception due to insider selling.
• While the sale was pre-planned, it still represents a reduction in the insider's direct equity stake.

Future Outlook

No specific future outlook or guidance was provided in this Form 4 filing, as it primarily reports an insider transaction.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or relate to industry trends or competitors. Insider transactions are common across all industries for various personal financial planning reasons.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a signal, potentially leading to a slight negative sentiment or increased scrutiny of the company's performance.

Key Dates

Recommendation

While the sale of shares by a President and COO could be a negative signal, the transaction was executed under a Rule 10b5-1 trading plan, indicating it was pre-scheduled and not necessarily based on new, adverse material information. Investors should monitor future insider activity and company performance, but this single, pre-planned sale does not warrant an immediate 'sell' recommendation. A 'hold' stance is appropriate, advising investors to maintain their current position while observing further developments.

Keywords

Xeris Biopharma Holdings, XERS, Kevin McCulloch, Insider Trading, Form 4, Stock Sale, Rule 10b5-1, Officer Transaction, Biopharma